Skip to content
Inciteful Med

Daily Management and Preventive Care

Last updated:

Daily preventive care is essential for managing sickle cell anemia at all ages. Hydroxyurea is the cornerstone medication to reduce pain crises, while children require strict monitoring with daily penicillin until age 5 and annual TCD ultrasounds to prevent severe complications like stroke.

Key Takeaways

  • • Hydroxyurea is a daily medication for both children and adults that helps prevent red blood cells from sickling by boosting fetal hemoglobin.
  • • Children with sickle cell disease need twice-daily penicillin from 2 months until age 5 to prevent life-threatening bacterial infections.
  • • Annual Transcranial Doppler (TCD) ultrasounds are critical for children ages 2 to 16 to assess and manage stroke risk.
  • • Newer medications like voxelotor, L-glutamine, and crizanlizumab offer additional options for older children and adults to manage symptoms and anemia.
  • • Keeping up with pneumococcal vaccines and getting regular eye exams are vital parts of routine health maintenance for sickle cell patients.

Preventative care in sickle cell disease (SCD) is about staying ahead of the condition. Because the care timeline changes as a patient grows, it is important to understand which preventative steps apply to children and which apply to adults [1][2].

Care for All Ages: Hydroxyurea

Hydroxyurea is the cornerstone medication for people with sickle cell anemia (HbSS and HbSβ0HbS\beta^{0}), applicable to both children and adults. It is a daily pill or liquid that works primarily by “turning back on” the production of fetal hemoglobin (HbF) [3][4].

  • How it helps: Higher levels of HbF prevent red blood cells from sickling, which leads to fewer pain crises, fewer hospital stays, and a lower risk of lung complications like Acute Chest Syndrome [3][5].
  • When to start: Guidelines recommend offering Hydroxyurea to infants as early as 9 months of age [6][7]. Starting early helps protect organs and supports normal growth [3][8].
  • Family Planning Warning: Hydroxyurea is teratogenic, meaning it can cause birth defects. Both male and female adults taking this medication must use reliable contraception and discuss family planning with their doctor before trying to conceive [3][9].

Pediatric Care: Preventing Infections and Stroke

Young children are uniquely vulnerable to specific complications that require strict monitoring.

Penicillin (Ages 0 to 5)

Because SCD damages the spleen, children are at high risk for life-threatening bacterial infections [10][11].

  • The Routine: Children should take a dose of liquid penicillin twice a day, starting by 2 months of age [1].
  • The Age 5 Milestone: Most children can safely stop taking daily penicillin at age 5, provided they have completed their basic vaccine series and have not had a major invasive infection or a surgical spleen removal [1][12].

The TCD Ultrasound (Ages 2 to 16)

One of the most important screenings for children with SCD is the Transcranial Doppler (TCD) ultrasound. This is a painless test that measures the speed of blood flow in the brain to assess stroke risk [13][14].

  • The Schedule: Children with HbSS or HbSβ0HbS\beta^{0} should have a TCD once a year starting at age 2 and continuing until age 16 [1][15].
  • Understanding the Results:
    • Low Risk (Normal): Speed is less than 170 cm/s [16].
    • Conditional Risk: Speed is 170–199 cm/s (requires more frequent screening) [17].
    • High Risk (Abnormal): Speed is 200 cm/s or higher. This indicates a high risk of stroke and usually requires starting a regular blood transfusion program [18][19].

Care for All Ages: Routine Health Maintenance

  • Vaccines: Keeping up with the latest vaccines (such as PCV20 or the series of PCV15 and PPSV23) is critical for both children and adults to protect against pneumonia and blood infections [20][21].
  • Eye Exams: Because sickled cells can damage the blood vessels in the back of the eye (retinopathy), patients—especially those with the HbSC subtype—need regular comprehensive eye exams by an ophthalmologist [22][23].

Newer Medications for Adults and Older Children

While Hydroxyurea is the standard, newer medications offer more options for managing SCD, primarily for older children and adults:

Medication How it Works Primary Benefit
Voxelotor Helps oxygen stick to hemoglobin so cells stay round [24]. Increases hemoglobin levels (reduces anemia) [25].
L-glutamine Reduces “oxidative stress” (internal damage) in red blood cells [26]. Reduces the number of pain crises and hospital visits [27].
Crizanlizumab Prevents blood cells from sticking to the walls of blood vessels [28]. Reduces the frequency of pain crises [29].

These medications can sometimes be used alongside Hydroxyurea to provide even better protection [30][31].

Frequently Asked Questions

When should my child start taking hydroxyurea for sickle cell anemia?
Guidelines recommend offering hydroxyurea to infants as early as 9 months of age. Starting this medication early helps protect organs and supports normal growth by preventing red blood cells from sickling.
Why do children with sickle cell anemia need to take daily penicillin?
Sickle cell disease damages the spleen, putting young children at a high risk for life-threatening bacterial infections. Taking a daily dose of liquid penicillin from 2 months to 5 years of age provides essential protection against these infections.
What is a TCD ultrasound and why does my child need it?
A Transcranial Doppler (TCD) ultrasound is a painless test that measures blood flow speed in the brain to assess stroke risk. Children with sickle cell anemia should have this screening once a year between the ages of 2 and 16.
What do the results of a TCD ultrasound mean?
A normal TCD speed is less than 170 cm/s. Speeds of 200 cm/s or higher indicate a high risk of stroke, which usually requires starting a regular blood transfusion program to keep the child safe.
Are there other medications besides hydroxyurea for adults with sickle cell?
Yes, newer medications like voxelotor, L-glutamine, and crizanlizumab are available for adults and older children. These treatments can help increase hemoglobin levels, reduce internal cell damage, and lower the frequency of pain crises.

Questions for Your Doctor

  • • Is my child ready to start Hydroxyurea? If we start early, what dose will they begin with?
  • • Can we review my child's most recent TCD score? Was it below 170 cm/s, and when is the next screening scheduled?
  • • Since my child is turning five, is it safe to stop the daily penicillin, or does their specific history mean we should continue it?
  • • Would adding Voxelotor or L-glutamine to my current adult treatment plan help reduce my symptoms further?
  • • Am I up to date on the latest pneumococcal vaccines (like PCV20), and do I need a booster?
  • • How often should I be getting a comprehensive eye exam to check for retinopathy?

Questions for You

  • • How consistently have I (or my child) been taking daily medications like penicillin or Hydroxyurea?
  • • Do I have the date of my (or my child's) last TCD ultrasound recorded, and do I know the result?
  • • Have I noticed any side effects from Hydroxyurea, such as stomach upset or changes in blood counts, that I should discuss with my doctor?
  • • What are my goals for treatment? Am I more concerned about preventing pain crises or improving my overall energy levels?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Management of Sickle Cell Disease: Recommendations from the 2014 Expert Panel Report.

    Yawn BP, John-Sowah J

    American family physician 2015; (92(12)):1069-76.

    PMID: 26760593
  2. 2

    Fostering a healthier generation of children with sickle cell disease through advancements in care.

    Franco E, Nimura C, McGann PT

    Pediatric research 2025; (97(4)):1280-1289 doi:10.1038/s41390-024-03566-w.

    PMID: 39271903
  3. 3

    Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety.

    Fogliazza F, Berzieri M, Carbone G, et al.

    Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238599.

    PMID: 41375902
  4. 4

    Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties.

    Garnier Y, Ferdinand S, Garnier M, et al.

    Blood 2020; (136(2)):247-256 doi:10.1182/blood.2020004853.

    PMID: 32285120
  5. 5

    Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

    Cannas G, Poutrel S, Thomas X

    Mediterranean journal of hematology and infectious diseases 2017; (9(1)):e2017015 doi:10.4084/MJHID.2017.015.

    PMID: 28293403
  6. 6

    Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial.

    Hood AM, Strong H, Nwankwo C, et al.

    JMIR research protocols 2021; (10(5)):e27650 doi:10.2196/27650.

    PMID: 34018965
  7. 7

    Hydroxyurea for Children with Sickle Cell Disease: A Practical Guide for Pediatric Clinicians.

    Coyne F, Strouse JJ

    Pediatric clinics of North America 2026; (73(1)):29-41 doi:10.1016/j.pcl.2025.08.007.

    PMID: 41207740
  8. 8

    Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.

    Abraham AA, Lang H, Meier ER, et al.

    Pediatric blood & cancer 2019; (66(5)):e27601 doi:10.1002/pbc.27601.

    PMID: 30609269
  9. 9

    Common gynecological challenges in adolescents with sickle cell disease.

    Stimpson SJ, Rebele EC, DeBaun MR

    Expert review of hematology 2016; (9(2)):187-96 doi:10.1586/17474086.2016.1126177.

    PMID: 26613137
  10. 10

    Invasive Pneumococcal Disease in Patients With Sickle Cell Disease.

    Navalkele P, Özgönenel B, McGrath E, et al.

    Journal of pediatric hematology/oncology 2017; (39(5)):341-344 doi:10.1097/MPH.0000000000000858.

    PMID: 28538501
  11. 11

    SARS-CoV-2 with Influenza B Coinfection in a Patient with Sickle Cell HbSC Presenting with Painful Crisis: A Case Report.

    Ali EA, Fadul A, Subahi EA, et al.

    Cureus 2024; (16(3)):e56102 doi:10.7759/cureus.56102.

    PMID: 38618320
  12. 12

    Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era.

    Yee ME, Abel L, Kalmus G, et al.

    Pediatric blood & cancer 2025; (72(9)):e31881 doi:10.1002/pbc.31881.

    PMID: 40563215
  13. 13

    Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents - Selected U.S. States, 2019.

    Schieve LA, Simmons GM, Payne AB, et al.

    MMWR. Morbidity and mortality weekly report 2022; (71(39)):1241-1246 doi:10.15585/mmwr.mm7139e1.

    PMID: 36173745
  14. 14

    Pattern of Cerebral Blood Flow Velocity Using Transcranial Doppler Ultrasonography in Children with Sickle Cell Disorder in Lagos State, Nigeria.

    Adekunle MO, Animasahun AB, Diaku-Akinwumi IN, Njokanma OF

    Mediterranean journal of hematology and infectious diseases 2017; (9(1)):e2017050 doi:10.4084/MJHID.2017.050.

    PMID: 28894559
  15. 15

    Limited access to transcranial Doppler screening and stroke prevention for children with sickle cell disease in Europe: Results of a multinational EuroBloodNet survey.

    Voi V, Gutierrez-Valle V, Cuzzubbo D, et al.

    Pediatric blood & cancer 2024; (71(10)):e31190 doi:10.1002/pbc.31190.

    PMID: 38984411
  16. 16

    Optimizing Transcranial Doppler Screening for Stroke Prevention in Young African Children With Sickle Cell Disease.

    Tembo D, Moons P, Tshimanga T, et al.

    Pediatric blood & cancer 2025; (72(9)):e31861 doi:10.1002/pbc.31861.

    PMID: 40553485
  17. 17

    Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.

    Smart LR, Ambrose EE, Balyorugulu G, et al.

    Acta haematologica 2023; (146(2)):95-105 doi:10.1159/000526322.

    PMID: 35977532
  18. 18

    Central nervous system complications and management in sickle cell disease.

    DeBaun MR, Kirkham FJ

    Blood 2016; (127(7)):829-38 doi:10.1182/blood-2015-09-618579.

    PMID: 26758917
  19. 19

    Transcranial color Doppler in stroke-free adult patients with sickle cell disease.

    Graziadei G, Casoni FM, Annoni F, et al.

    Annals of hematology 2017; (96(9)):1547-1555 doi:10.1007/s00277-017-3071-1.

    PMID: 28730452
  20. 20

    Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.

    Kobayashi M, Pilishvili T, Farrar JL, et al.

    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2023; (72(3)):1-39 doi:10.15585/mmwr.rr7203a1.

    PMID: 37669242
  21. 21

    The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era.

    Chen CH, Chen CL, Su LH, et al.

    Human vaccines & immunotherapeutics 2025; (21(1)):2497611 doi:10.1080/21645515.2025.2497611.

    PMID: 40289536
  22. 22

    Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study.

    Brandsen RP, Diederen RMH, Bakhlakh S, et al.

    Blood advances 2023; (7(13)):3080-3086 doi:10.1182/bloodadvances.2022009147.

    PMID: 36897257
  23. 23

    A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea.

    Setayesh T, Chi M, Oestreicher Z, et al.

    Blood 2025; (146(1)):13-28 doi:10.1182/blood.2024028136.

    PMID: 40324066
  24. 24

    Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease.

    Alshurafa A, Yassin MA

    Frontiers in medicine 2022; (9()):931924 doi:10.3389/fmed.2022.931924.

    PMID: 36186817
  25. 25

    Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease.

    Yenamandra A, Marjoncu D

    Journal of the advanced practitioner in oncology 2020; (11(8)):873-877 doi:10.6004/jadpro.2020.11.8.7.

    PMID: 33489427
  26. 26

    A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

    Niihara Y, Miller ST, Kanter J, et al.

    The New England journal of medicine 2018; (379(3)):226-235 doi:10.1056/NEJMoa1715971.

    PMID: 30021096
  27. 27

    Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies.

    Yassin M, Minniti C, Shah N, et al.

    Blood reviews 2025; (73()):101298 doi:10.1016/j.blre.2025.101298.

    PMID: 40307078
  28. 28

    Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.

    Han J, Saraf SL, Gordeuk VR

    Pharmacotherapy 2020; (40(6)):535-543 doi:10.1002/phar.2409.

    PMID: 32350885
  29. 29

    Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.

    Ali MA, Ahmad A, Chaudry H, et al.

    Experimental hematology 2020; (92()):11-18.e1 doi:10.1016/j.exphem.2020.08.008.

    PMID: 32841705
  30. 30

    The GLOBE Trial: Efficacy and Safety of L-Glutamine Plus Hydroxyurea Versus Hydroxyurea Alone in Sickle Cell Anemia - A Double-Blind, Randomized Study.

    Shakibazad N, Momenzadeh M, Amiri B, et al.

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2026; doi:10.4274/tjh.galenos.2026.09709.

    PMID: 41664386
  31. 31

    Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

    Dick MH, Abdelgadir A, Kulkarni VV, et al.

    Cureus 2022; (14(5)):e24920 doi:10.7759/cureus.24920.

    PMID: 35706735

This page is for informational purposes only and does not replace professional medical advice. Always consult your hematologist or pediatrician regarding specific sickle cell treatments and screening schedules.

Stay up to date

Get notified when new research about Sickle cell anemia is published.

No spam. Unsubscribe anytime.